Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth

According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a CAGR...

RGBP : 0.0060 (+5.26%)
CRIS : 1.45 (-7.05%)
BPTH : 0.45 (unch)
ATHX : 1.90 (+1.60%)
BLRX : 0.68 (-2.86%)
Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid...

BPTH : 0.45 (unch)
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path: 2Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.7 million in its second quarter.

BPTH : 0.45 (unch)
Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path: 1Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.9 million in its first quarter.

BPTH : 0.45 (unch)
Bio-Path Holdings Reports First Quarter 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 1.11 (+3.74%)
BPTH : 0.45 (unch)
Bio-Path Leukemia Combo Study Shows Positive Early Data

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

LGND : 155.47 (-1.97%)
ENTA : 76.73 (+0.95%)
REGN : 346.56 (-2.83%)
BPTH : 0.45 (unch)
Bio-Path Holdings Reports Full Year 2017 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time.

BPTH : 0.45 (unch)
Bio-Path Holdings Announces Publication in The Lancet Haematology

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)
Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting

Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today...

BPTH : 0.45 (unch)
Bio-Path Holdings to Present at the 30th Annual ROTH Conference

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 0.45 (unch)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -19.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures saw fractional to 1 1/2 cent gains in most contracts on Monday. Support was mainly from strength in the wheat complex, even amongst a stronger dollar. USDA in DC was closed today in observation of Veterans Day, as were many banks. The tr...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar